Apnat 60 mg contains Apalutamide, a next-generation androgen receptor inhibitor used in the management of prostate cancer. It offers a targeted therapy approach, specifically designed for men with non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic castration-sensitive prostate cancer (mCSPC).

By interfering with the action of androgens (male hormones), which fuel the growth of prostate cancer cells, Apalutamide plays a vital role in slowing disease progression and improving survival outcomes.

Mechanism of Action

Apalutamide works by selectively inhibiting the androgen receptor (AR).

Here’s how it acts:

• It competitively binds to androgen receptors on prostate cancer cells.

• This blocks the binding of natural androgens like testosterone and dihydrotestosterone (DHT).

• By preventing AR activation and its translocation into the cell nucleus, Apalutamide halts the transcription of genes that drive prostate cancer cell growth and survival.

  Uses / Indications

  Apnat 60 mg is primarily indicated in men with:

  Approved indications:

  • Non-metastatic castration-resistant prostate cancer (nmCRPC)
    → Patients whose cancer is progressing despite low testosterone levels but hasn’t spread.

  • Metastatic castration-sensitive prostate cancer (mCSPC)
    → Used in combination with androgen deprivation therapy (ADT) in newly diagnosed metastatic disease.

    Adverse Effects

    While generally well tolerated, Apalutamide may cause side effects due to its strong anti-androgenic activity and impact on metabolic and neurological functions.

    Common side effects:

    • Fatigue

    • Joint pain (arthralgia)

    • Hot flashes

    • Diarrhoea

    • Weight loss

    • Hypertension

    Less common but serious:

    • Seizures (rare – more likely in patients with predisposing conditions)

    • Falls and fractures (especially in elderly)

    • Hypothyroidism

    • Skin rash (occasionally severe)